FDA escalates recall of blood pressure drug amid carcinogen concerns—yet another failure in Big Pharma’s toxic empire
The FDA upgraded its recall of metoprolol succinate, a widely prescribed blood pressure drug, from Class III to Class II due to potential carcinogenic risks and dissolution failures, indicating a higher likelihood of adverse health effects.
The recall highlights vulnerabilities in global drug supply chains, particularly from Indian manufacturers, where sanitation failures, contamination risks and falsified data persist despite prior FDA warnings.
Neither Teva Pharmaceuticals nor Amerisource Health Services issued public warnings, leaving patients uninformed about risks—a pattern of Big Pharma suppressing negative data to avoid liability.
The FDA’s delayed action and contradictory messaging (admitting cancer risks while claiming harm is “remote”) reflect deep-seated corruption, with regulators prioritizing corporate interests over public safety.
The recall underscores the need for transparency, accountability and access to safer, natural cardiovascular therapies (e.g., hawthorn, magnesium) while exposing the dangers of a profit-driven medical system reliant on toxic synthetics.
Read Full Article: https://www.naturalnews.com/2026-03-10-fda-escalates-recall-of-blood-pressure-drug.html
